Molecularly, the Arginine–glycine–aspartic acid (RGD)‐containing cadherin 6 (CDH6, K‐cadherin) is often highly expressed and has been determined in 70% of high‐grade serous, 45% of low‐grade serous, 27% of clear cell, 25% of endometrioid, and 3.6% of mucinous cases, with a preferential expression in stage III cancers, except for high‐grade serous, which show invariably high expression [7]. The gene discussed is CDH6; the disease is cancer.